39 results about "Sympathetic activity" patented technology

Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated to increase the parasympathetic activity / sympathetic activity ratio in a manner that is effective to treat the subject for the condition. Certain embodiments include modulating at least a portion of a subject's autonomic nervous system by inhibiting and / or increasing activity in at least a portion of the subject's autonomic nervous system. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.

Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is electrically modulated to increase the parasympathetic activity / sympathetic activity ratio in a manner that is effective to treat the subject for the condition. Certain embodiments include electrically modulating at least a portion of a subject's autonomic nervous system by inhibiting and / or increasing activity in at least a portion of the subject's autonomic nervous system. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.

Methods for treating a renal associated disease condition in a subject are provided. The subject methods are characterized by modulating at least one portion of the subject's autonomic nervous system in a manner effective to treat a renal condition in the subject. Specifically, the methods may include modulating, e.g., increasing, a parasympathetic / sympathetic activity ratio in the subject. Also provided are compositions, kits and systems for practicing the subject methods.

Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity / sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and / or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.

Devices and methods that regulate the innervation of the kidney by detection and modification of the aorticorenal ganglion. Devices for percutaneous detection and treatment of the aorticorenal ganglion via a blood vessel to modify renal sympathetic activity.

Methods for treating a patient using therapeutic spinal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves of one or more targeted organs proximate one or more dorsal root ganglia, stellate ganglia, vertebral ganglia, or cervical ganglia of the nerves using an intravascularly-positioned therapeutic element. One or more measurable physiological parameters corresponding to at least one condition associated with sympathetic activity in the targeted organs and / or central sympathetic activity in the patient can thereby be reduced.

Devices and methods that regulate the innervation of the kidney by detection and modification of the aorticorenal ganglion. Devices for percutaneous detection and treatment of the aorticorenal ganglion via a blood vessel to modify renal sympathetic activity.

An autonomic nervous activity monitor capable of predicting occurrence of abnormal reaction depending on autonomic nervous activity and used for medical practice and the like is provided. A blood component collecting apparatus 100 carries out frequency analysis to a pattern of heartbeat which is acquired by an ECG 300 from a donor, and calculates a high frequency component value [msec2] defined as an indicator for parasympathetic activity and a ratio value of a low frequency component to the high frequency component defined as an indicator for sympathetic activity to detect a change in these values on a time-series base. When a judgment circuit 204 predicts that abnormal reaction may occur to a donor after blood collection operation is started, a controller 200 controls a pump 9 to decrease a blood drawing or blood returning speed, or, to stop blood drawing or blood returning operation.

Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity / sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and / or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.

An apparatus, a method and a computer program for the determination of sympathetic activity are disclosed. The method comprises: receiving heart activity data of a person; determining a recovery heart rate change speed during a recovery heart rate period in the heart activity data; and determining a sympathetic activity state of the sympathetic nervous system of the person based on the determined recovery heart rate change speed.

Multi-dose active agent packages and methods for using the same for treating a subject for a condition are provided. Aspects of the invention include a multi-dose active agent package containing a plurality of unit dosage forms of an active agent configured to modulate at least a portion of a subject's autonomic nervous system during at least one season of the year. The active agent is present in an amount sufficient to alter the parasympathetic activity / sympathetic activity ratio of the subject in a manner effective to treat the subject for the condition. The subject active agent packages and methods find use in the treatment of a variety of different conditions, including disease conditions that increase in severity and / or occurrence during one or more seasons of the year. Also provided are kits for use in practicing the subject methods.

A method, apparatus and computer program product are disclosed for non-invasively determining blood pressure of a subject. To improve the specificity of automatic blood pressure determinations in a patient monitor provided with a non-invasive blood pressure determination unit, a physiological index indicative of sympathetic activity is derived from a subject, variations in the physiological index are monitored, and the blood pressure determination unit is instructed to initiate blood pressure determination when the variations fulfill a predetermined condition.

The present invention provides pharmaceutical compositions comprising antagonists of hepatic sympathetic activity and methods for using said pharmaceutical compositions for treatment of hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridaemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, renal failure, sexual dysfunction, chronic stress, and anxiety.

An autonomic nervous activity monitor capable of predicting occurrence of abnormal reaction depending on autonomic nervous activity and used for medical practice and the like is provided. A blood component collecting apparatus 100 carries out frequency analysis to a pattern of heartbeat which is acquired by an ECG 300 from a donor, and calculates a high frequency component value [msec2] defined as an indicator for parasympathetic activity and a ratio value of a low frequency component to the high frequency component defined as an indicator for sympathetic activity to detect a change in these values on a time-series base. When a judgment circuit 204 predicts that abnormal reaction may occur to a donor after blood collection operation is started, a controller 200 controls a pump 9 to decrease a blood drawing or blood returning speed, or, to stop blood drawing or blood returning operation.

Devices and methods that regulate the innervation of the kidney by detection and modification of the aorticorenal ganglion. Devices for percutaneous detection and treatment of the aorticorenal ganglion via a blood vessel to modify renal sympathetic activity.

A system and method for analyzing a subject health condition based on an input signal comprising subject heartbeat data recorded from the subject over a time period. Using the subject heartbeat data, a sympathetic activity index value in a sympathetic activity index (SAI) determined, where the SAI represents an influence, on a mean heart rate of the subject, of sympathetic nerve activity (SNA) of the subject.

This invention relates to the treatment of neuropsychiatric disorders in sufferers thereof. Neuropsychiatric disorders are shown to be treatable using a biofeedback method in which sympathetic activity in the patient is enhanced.

The present disclosure relates to devices and methods for stimulating peripheral nerves in a patient via electrical, optical, mechanical, or other stimulation, in order to change the balance between parasympathetic and sympathetic activity by selectively increasing or decreasing each of parasympathetic and sympathetic activity. In a particular application, the present disclosure relates to a device for transdermal stimulation of the vagus nerve (including the auricular branch) to selectively affect the sympathetic and parasympathetic nervous system to achieve the desired therapeutic effect ina human subject.

A method, apparatus and computer program product are disclosed for non-invasively determining blood pressure of a subject. To improve the specificity of automatic blood pressure determinations in a patient monitor provided with a non-invasive blood pressure determination unit, a physiological index indicative of sympathetic activity is derived from a subject, variations in the physiological index are monitored, and the blood pressure determination unit is instructed to initiate blood pressure determination when the variations fulfill a predetermined condition.

The invention discloses a pharmaceutical formulation for treating cardiovascular diseases. The pharmaceutical formulation comprises chondroitin sulfate, notopterygium root, cornua cervi pantotrichum, honeysuckle, radix scrophulariae, sucrose octaacetate, orange essence, agastache rugosus essence, betacyclodextrin, longstamen onion bulb, hawthorn, corydalis tuber, radix pueraiae, red flower, peach kernel, ginkgo leaf, selfheal, pine needle, sophora japonica, chrysanthemum indicum, pig's bile, dried white peony root, H2 receptor antagonist and beta 1 receptor antagonist. The pharmaceutical formulation has the advantages that the beta 1 receptor antagonist and the H2 receptor antagonist are combined with the traditional Chinese medicine to prepare new compound drug preparation, the preparation has a sympathetic activity resisting effect in vivo, and the effect directions are consistent; due to the fact that effect targets of the beta 1 receptor antagonist and the H2 receptor antagonist are different, effective synergy is achieved, that is to say, the use amount of the beta 1 receptor antagonist and the H2 receptor antagonist can be reduced, toxic and side effect occurrence rate can be lowered, curative effect can be brought into play through various channels, effective therapeutic effects on the cardiovascular diseases including coronary heart diseases, arrhythmia, hypertension and congestive heart failure can be achieved, and the pharmaceutical formulation is worthy of popularization and application.

A biometric information presentation system that enables efficient training by obtaining biometric information without giving a subject a sense of discomfort. The biometric information presentation system uses a garment-type biometric information measuring apparatus including at least fabric having a 20% elongation stress of 20 N or less. A garment pressure of the garment-type biometric information measuring apparatus is 0.1 kPa or more and 1.5 kPa or less. A skin contact-type electrode is provided at a portion of the garment-type biometric information measuring apparatus at which a garment pressure is 0.3 kPa or more. The garment-type biometric information measuring apparatus is worn by the subject. From obtained electrocardiographic information is calculated an RRI, an indicator of parasympathetic activity and indicator of sympathetic activity. The biometric information presentation system presents this calculated result on a terminal device and presents an action based upon the result to achieve the efficient training.

Methods of treating a psychiatric disorder in a subject are provided which include placing at least one anode on an area of the subject's back over the dorsal spinal cord at the level of one or more of: thoracic vertebra 7 (T7), 8 (T8), 9 (T9), 10 (T10), 11 (T11), and 12 (T12) and lumbar vertebra 1 (L1); placing at least one cathode on an area of the subject's back which is generally rostral with reference to the anode; connecting the anode and the cathode to at least one source of direct and / or alternating electrical current; delivering direct current to the anode for a treatment period of time, the treatment period of time defining a tsDCS and / or tsACS treatment session, thereby modulating spinal input to the brain of the subject, decreasing sympathetic activity and reducing one or more symptoms and / or comorbidities associated with the psychiatric disorder.